MDM2 Splice Variants and Their Therapeutic Implications

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|5|1|21-26

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.5, Iss.1, 2005-02, pp. : 21-26

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cellular activity of dopamine DA2 receptor splice variants and mutants

By Fraeyman N.H.   Vermis K.  

Pharmacological Research, Vol. 48, Iss. 5, 2003-11 ,pp. : 535-540

Elsevier

Access to resources Recommend Favorite

Therapeutic considerations for Mdm2: not just a one trick pony

By Lehman Jason A   Eitel Jacob A   Batuello Christopher N   Mayo Lindsey D  

Expert Opinion on Drug Discovery, Vol. 3, Iss. 11, 2008-11 ,pp. : 1309-1321

Informa Healthcare

Access to resources Recommend Favorite

The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies

By  

Current Pharmaceutical Design, Vol. 14, Iss. 21, 2008-07 ,pp. : 2100-2110

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial [Hot Topic: MDM2 as a Cancer Therapeutic Target (Guest Editor: Ruiwen Zhang)]

By  

Current Cancer Drug Targets, Vol. 5, Iss. 1, 2005-02 ,pp. : 1-2

Bentham Science Publishers

Access to resources Recommend Favorite

MDM2 Non-Genotoxic Inhibitors as Innovative Therapeutic Approaches for the Treatment of Pediatric Malignancies

By  

Current Medicinal Chemistry, Vol. 20, Iss. 17, 2013-06 ,pp. : 2226-2236

Bentham Science Publishers

Access to resources Recommend Favorite